Waldencast Reports Strong H1 2025 Growth and Strategic Initiatives

Waldencast ( (WALD) ) just unveiled an announcement.

On August 18, 2025, Waldencast plc announced strong progress on its business priorities for the first half of 2025, highlighting significant revenue growth and strategic initiatives. Obagi Medical achieved double-digit growth in core channels and expanded its market through the acquisition of Novaestiq Corp., while Milk Makeup saw robust retail sales in the U.S. Despite challenges in international markets and supply chain constraints, the company remains optimistic about future growth. Waldencast also initiated a strategic review to explore alternatives for enhancing shareholder value and postponed its H1 2025 earnings release to finalize this review.

The most recent analyst rating on (WALD) stock is a Hold with a $4.30 price target. To see the full list of analyst forecasts on Waldencast stock, see the WALD Stock Forecast page.

Spark’s Take on WALD Stock

According to Spark, TipRanks’ AI Analyst, WALD is a Neutral.

Waldencast Acquisition’s overall score reflects a challenging financial position, with ongoing profitability and cash flow issues being significant concerns. The technical analysis indicates bearish trends, further compounded by valuation challenges due to negative earnings. While the earnings call provides some optimism about future growth, immediate financial and operational hurdles remain.

To see Spark’s full report on WALD stock, click here.

More about Waldencast

Waldencast plc is a global multi-brand beauty and wellness platform primarily focused on skincare and makeup products. The company operates brands like Obagi Medical and Milk Makeup, with a market focus on strategic channels and digital expansion.

Average Trading Volume: 147,215

Technical Sentiment Signal: Sell

Current Market Cap: $212.3M

For an in-depth examination of WALD stock, go to TipRanks’ Overview page.